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Review
Following Russel Ross [1], there is now general agreement
that vessel wall inflammation constitutes a major factor in
the development of atherosclerosis, atheroma instability
and plaque disruption followed by local thrombosis, that
underlies the clinical presentation of acute coronary syn-
dromes [2–4]. Endothelial-cell injury is the main stimulus
for development of the atherosclerotic plaque: an inflam-
matory-fibroproliferative response results from various
forms of insult to the endothelium.
Arterial endothelium changes rapidly in response to spe-
cific stimuli. Elevated and modified LDL, cigarette smok-
ing, hypertension, diabetes mellitus, genetic alterations,
increase of plasma homocysteine, and infectious microor-
ganisms such as herpes virus or Chlamydia pneumoniae,
were considered by Ross as possible causes of endothelial
dysfunction [1]. In atherosclerosis and other diseases, dys-
functional vascular endothelium leads to leukocyte
recruitment. The initial phase of inflammation is usually
silent and the atherosclerosis preclinical window is fairly
long. In altered arterial endothelium there is increased
monocyte adhesion as well as impaired nitric oxide pro-
duction and vascular relaxation [5]. Adherence of mono-
cytes to the endothelial surface is facilitated by the
expression of the adhesion molecules vascular cell adhe-
sion molecule-1 (V-CAM 1) and intercellular adhesion
molecule-1 (ICAM-1).
Endothelial function is a balance between vascular cell
protectors and risk factors. Under physiological condi-
tions, vascular endothelium has antithrombogenic poten-
tial. Activation of endothelia cells by proinflammatory
cytokines or infectious agents is associated with a loss of
antithrombotic properties. Endothelial dysfunction,
injury and inflammation induce cell imbalance and a nor-
mal endothelium with anticoagulant properties becomes
prothrombotic. Endothelial dysfunction is associated
with a decrease of nitric oxide and an increase of oxidative
stress, an important promotor of the inflammatory proc-
ess [6,7] Risk factors, either acute (infection, immune
local reaction) or permanent (hypertension, diabetes, dys-
lipemia, obesity, hyperhomocysteinemia, smoking, etc)
induce endothelial dysfunction, cell injury, and a proin-
flammatory environment resulting in a local, tissue factor
mediated activation of the clotting cascade [6,8,9]. In
addition, it seems that expression of tissue factor in
endothelial cells and monocytes is partly regulated by the
proinflammatory cytokines tumor necrosis factor and
interleukin-1. Also, interaction of tissue factor and P-
selectin accelerates the rate and extent of fibrin formation
[10].
In the presence of cardiovascular risk factors, not all indi-
viduals respond with an arterial thrombotic process, sug-
gesting that several additional factors might be involved
in coronary events; for instance, behavior of plasmatic
coagulation activation, local blood flow conditions (shear
stress), circulating progenitor cells, and genetic factors.
Inappropriate generation of thrombin may lead to vascu-
lar occlusion [11]. In the atheroma environment, proco-
agulant and anti-coagulant forces together with pro / anti
fibrinolytic substances determine a delicate balance.
Hereditary or acquired defects of blood clotting factors,
impairment of the anticoagulant system or fibrinolytic
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mechanism, and inflammation, could promote plasmatic
and local hypercoagulation state. Local thrombin genera-
tion not only results in a mixed, fibrin/platelets clot but
thrombin itself has proinflammatory activity [12]. Plaque
in unstable angina possesses elevated levels of tissue fac-
tor that could be released during inflammation, precipi-
tating acute clinical syndromes.
Local hemodynamic forces play an important role in
thrombogenesis in at least two ways: first, physically, as
modulators of endothelial function [13,14] by decreasing
the vasodilator substances prostacyclin and nitric oxide,
or by increasing the vasocontrictor endothelin-1; second,
as in situ modulators of clotting balance (triggering plate-
let activation and over-expression of tissue factor), of
fibrinolysis, and of thrombin generation.
The role of inflammation in thrombosis probably varies
according to the pathogenesis of the syndrome. With the
focus on coronary occlusive disease, there are other ori-
gins of thrombotic events beside plaque rupture [15,16].
In atheroma the luminal surface is irregular and some-
times eroded, and the lack of endothelial cells constitutes
a vulnerable site, as prone to acute thrombosis as lipid-
rich plaques are [17]. The flow zone distal to the apex of
the plaque, characterized as a "low shear-stress" region, is
prone to fibrinogen deposition [18] and involves areas of
flow recirculation, stagnation points and flow reversal,
with changes in the metabolic activities of endothelial
cells [19]. Blood turbulence produces platelet and clotting
activation, accelerates thrombin formation and promotes
a mixed thrombus [14]. In these circumstances, platelets
are not only involved in haemostasis but also in initiating
the inflammatory response.
CD40 ligand (CD40L, CD154), a transmembrane protein
structurally related to the cytokine TNF-alpha, is of para-
mount importance in the development and function of
the humoral immune system. Activated platelets express
CD40L and induce endothelial cells to secrete chemok-
ines and to express adhesion molecules, indicating that
platelets could initiate an inflammatory response of the
vessel wall [20].
According to a recent report, bone marrow cells give rise
to most of the smooth muscle cells that contribute to
plaque formation [21]. Circulating endothelial progenitor
cells contribute to the repair capacity of endothelium
[22]. Whether endothelial injury in the absence of suffi-
cient circulating progenitor cells affects the balance
between injury and the repair capacity of endothelium,
determining the progression of the lesion and of cardio-
vascular disease, is a matter of debate [22] that may pro-
vide important insights into the links between
inflammation and atherosclerosis.
Genetic predisposition to atherosclerosis was studied in
the general population, using carotid artery intima-media
thickness as a measure. A positive parental history of myo-
cardial infarction or stroke was associated with increased
carotid artery thickness at specific sites in the carotid tree,
independently of conventional risk factors [23,24]. Fol-
low-up studies of coronary stenting provided additional
support for the central role of inflammation. Indeed, stent
produces a prolonged, intense inflammatory state with
recruitment of leukocytes, mainly monocytes. There is
strong link between the extent of medial damage, inflam-
mation and restenosis [25]. Additional data were reported
by Moreno et al. [26]. These authors found a positive cor-
relation between the number of macrophages present in
the tissue at the time of angioplasty and the propensity for
restenosis.
Markers of Inflammation
As result of chronic inflammation, numerous markers
such as CPR (C-reactive protein), cytokines (interleukin-6
and 18, tumor necrosis factor α), adhesion molecules
(ICAM-1), E-selectin and acute-phase reactants related to
the clotting system (e.g. fibrinogen) are increased in
plasma, possible predictors of further cardiovascular
events [27–32]. Interleukin-18 plays a key role in the
inflammation cascade and is an important regulator of
both innate and acquired immunities [33]. It induces the
production of interferon-γ and T-lymphocytes, has been
found in human atherosclerotic lesions, and was identi-
fied as a strong independent predictor of death from car-
diovascular causes in patients with stable as well as
unstable angina. Inhibition of interleukin-18 reduced
lesion progression with a decrease of inflammatory cells.
Matrix metalloproteinase (MMP-9) (gelatinase B),
secreted by macrophages and other inflammatory cells,
has been identified in various pathological processes such
as general inflammation, tumor metastasis, respiratory
diseases, myocardial injury, vascular aneurysms, and
remodeling. MMP-9 is elevated in patients with unstable
angina [34]. Blankenberg et al. [35] noted a strong associ-
ation between baseline MMP-9 levels and future risk of
CV death, independent of IL-18. Combined determina-
tion of MMP-9 and IL-18 identifies patients at very high
risk.
Proinflammatory cytokines derived from monocytes,
macrophages and/or adipose tissue trigger CRP in the
liver. C-Reactive protein is an acute-phase reactant, a
marker of inflammation, and predicts early and late mor-
tality in patients with acute coronary syndromes. It is an
independent predictor of future cardiovascular events
[36]. CRP itself promotes inflammation [37] and athero-
genesis via effects on monocytes and endothelial cells and
increasing the concentration and activity of plasminogenThrombosis Journal 2003, 1 http://http//www.thrombosisjournal.com/content/1/1/4
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activator inhibitor-1 [38]. CRP in atheroma participates in
the pathogenesis of unstable angina and restenosis after
coronary intervention [39]. Thus, there is a vicious circle:
inflammation releases proinflammatory cytokines, which
in turn maintain inflammation. In a subset of healthy
men in the Physicians Health study, the benefit of aspirin
(325 mg/day every other day) was most significant in
patients within the highest quartile of C-reactive protein
elevation compared with the lowest quartile. In patients
with coronary artery disease, aspirin also seems to reduce
C-reactive protein levels [40]. Components of the meta-
bolic syndrome (obesity, hypertension, hypertriglyceri-
demia, low HDL, abnormal glucose) are associated with
increased levels of CRP and add prognostic information
on further cardiovascular events [41]. Statin as aspirin
therapy was particularly effective among patients with
high CRP levels [30]. It seems clear that CRP is a marker
for risk for cardiovascular events, but whether it should be
used in routine screening is still a matter of debate [42–
45].
Inflammation Mediate Risk Factors
Pleiotropic atheroprotective activity of specific treatments involving 
antiinflammatory properties
Diabetes
Although diabetes mellitus is primarily a metabolic disor-
der, it is also a vascular disease [46].
The most important cause of death among diabetic
patients is cardiovascular complication. Comparing dia-
betic patients with non-diabetic patients both with or
without prior history of cardiovascular events, Haffner et
al. [47] showed, after a follow-up of 7 years, that mortality
in diabetic patients was higher than in non-diabetics and
that for diabetic patients with no history of myocardial
infarction, the risk of myocardial infarction was similar to
that of non-diabetic patients who did have such a history.
These data suggest that diabetic patients have already
developed vascular disease by the time of clinical diagno-
sis [46]. Although type 2 diabetes is a state of increased
plasma coagulability [48], it is clear that endothelial dys-
function is the most important factor in thrombotic com-
plications. It is present mainly in type 2 diabetes than type
1 [49,50]. The so called metabolic syndrome, a concur-
rence of disturbed glucose and insulin metabolism, over-
weight and abdominal fat distribution, moderate
dyslipemia and hypertension, might be responsible for
the vascular endothelial dysfunction. Indeed, cardiovas-
cular disease and all causes of mortality are increased in
men with metabolic syndrome [51].
As indicators that the endothelium is compormised,
microalbuminuria and proteinuria are frequently present
in diabetic patients and constitute predictors of cardiovas-
cular events and ischemic stroke [52–54]. Hyperglycemia
and production of advanced glycation end products
(AGE) are probably the most important factors, if not the
only factors, in endothelial dysfunction in diabetics. By
binding specific receptors (RAGE), AGE induces the
expression of different proinflammatory molecules.
Endothelial dysfunction could be also consequence of the
dyslipidemia frequently present in type 2 diabetes and
oxidative stress [55].
Diabetic patients have impaired endothelium-dependent
vasodilatation, hyper-coagulability, increased PAI-1 level
in the arterial wall with impaired fibrinolysis, decrease of
endothelial nitric oxide synthase, and increase of
endothelin-1 [56]. Platelets are larger, with an increased
number of glycoprotein IIb-IIIa receptors in the mem-
brane, and are hyper-reactive and show enhanced biosyn-
thesis of thromboxane A2 [57,58]. Platelets from diabetic
subjects behave abnormally, showing increased adhesive-
ness as well as spontaneous and agonist-induced aggrega-
tion, reflected by abnormalities in platelet function tests
[59,60]. Von Willebrand factor, mainly synthesized by
endothelial cells and involved in platelet adhesion, is
increased, reflecting endothelial activation or damage
[61].
Although diabetic patients presented with thrombophilic
profiles, in diabetics with acute coronary syndromes with-
out ST-segment elevation, or following percutaneous cor-
onary intervention, inhibitors of the platelet receptors
glycoprotein IIb-IIIa reduced mortality compared with
non-diabetics. This remains unexplained at present and is
at odds with the hyper-reactivity of platelets seen in these
patients [62,63].
It is known that cytokine release and processes leading to
macrophage activation are enhanced in diabetics [64] and
contribute to the development of athero-inflammatory
complexes. The blood level of C-RP is generally higher in
diabetic patients than in normal populations indicating
that inflammation contributes to the development of the
disease [65]. Low grade inflammation is involved in the
pathogenesis of type-2 diabetes. Results from the MON-
ICA study [66] showed that men with CRP in the highest
quartile (≥ 2.91 mg/L) had a 2.7 times higher risk of devel-
oping diabetes than those in the lower quartile (≤ 0.67
mg/L).
Lastly, a novel group of antidiabetic drugs, thiazolidinedi-
ones, exhibit anti-inflammatory properties in addition to
their plasma glucose lowering effect. Type 2 diabetic
patients with coronary artery disease have high levels of
inflammatory markers, including serum C-reactive pro-
tein, metalloproteinase-9, white cells count, tumor necro-
sis factor-α and serum amyloid A [67,68]. Since treatment
with rosiglitazone significantly reduces theseThrombosis Journal 2003, 1 http://http//www.thrombosisjournal.com/content/1/1/4
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inflammatory markers it could indicate a link between
diabetes, coronary disease and inflammation.
Lipids
In atherosclerosis, signs of inflammation are accompa-
nied by incipient lipid accumulation in the artery wall
[69]. Several factors determine endothelial modifications
through a primary inflammatory response followed by a
local prothrombotic balance.
LDL oxidation is a main cause of endothelial injury and
induces the expression of proinflammatory molecules in
endothelial cells. Thus removal of modified LDL is impor-
tant in the treatment of the inflammatory response.
Several studies have reported high levels of total tissue fac-
tor pathway inhibitor (TFPI) antigen in patients with
serum elevated cholesterol. Increased TFPI inhibit the
extrinsic coagulation system, but the procoagulant system
may be activated concurrently. The median levels of total
TFPI, free TFPI, FVIIc and prothrombin fragments 1+2
were higher in hyperlipidemic patients than healthy sub-
jects. The increase of fragments 1+2 indicates a global
thrombophilic state [70,71]. These blood changes follow
the endothelial inflammatory reaction.
Other lipids have also active inflammatory effects; nota-
bly, high plasma levels of VLDL are associated with
increased risk of atherosclerosis. In this regard, Dichtl et al
[72] showed that VLDL (75 to 150 µg/mL) activates
nuclear factor-κB (NF-κB), a transcription factor known to
play a key role in regulation of inflammation, in cultured
human endothelial cells. There was also expression of
intercellular adhesion molecule-1 and vascular cell adhe-
sion molecule-1, as well as proinflammatory molecules
such as the cytokine tumor necrosis factor-α. Injected trig-
lycerides, precursors of LDL, also activate arterial expres-
sion of NF-κB. In line with this result, postprandial
hypertriglyceridemia is considered a risk factor for cardio-
vascular disease. It was suggested that postprandial hyper-
triglyceridemia induces endothelial dysfunction through
oxidative stress [73].
Lipoprotein (a) has a structure similar to that of plamino-
gen and may reduce plasmin generation and impair fibri-
nolysis, inducing a prothrombotic state. Elevated levels of
lipoprotein (a) might strongly predict endothelial dysfuc-
tion in normocholesterolemic and non-diabetic subjects
[74].
Oxidative inactivation of nitric oxide is regarded as an
important cause of endothelial lesion. Decreased nitric
oxide may favor platelet-adhesion/aggregation and arte-
rial thrombosis. One of the pathophysiological conse-
quences of platelet binding to LOX-1 may be the
inactivation of nitric oxide (NO) through increased cellu-
lar production of O2 [75].
Hydroxymethylglutaryl coenzyme A reductase inhibitors
(statins) reduce cardiovascular disease events and
improve outcomes. These benefits have been attributed to
their LDL-lowering (and potentially HDL-elevating)
effects. However, several trials have suggested that the
clinical benefit of statins is greater than expected from the
lowering effect on lipids [76]. Analysis of large clinical tri-
als indicates that statin-treated individuals have signifi-
cantly less cardiovascular disease irrespective of their
serum cholesterol levels and the treatment is particularly
effective among patients with high CRP levels [77,78].
Long-term statin therapy has been shown to reduce levels
of C-reactive protein in a lipid-independent manner [79].
Additional effects were observed: statins limit tissue factor
expression [80], normalize fibrinolytic activity, reduce
plaque inflammation and cause regression of human
atheroesclerotic lesions [81], improve coronary endothe-
lial function [82] and have antiinflammatory and antipro-
liferative effects [83]. In this regard, statins are potent
upregulators of endothelial cell nitric oxide synthase lev-
els and nitric oxide synthesis. In a rabbit model and in cul-
tured vascular smooth muscle cells, atorvastatin decreased
inflammatory mediators in the atherosclerotic lesion and
significantly downregulated COX-2 both in vitro and in
vivo [84]. Other effects may also be mediated through
nonlipid changes: Statins significantly increase circulating
endothelial progenitor cells [85], contributing to the
repair capacity of endothelium [21]. Also, statins exert
beneficial effects in vascular diseases by inhibition of leu-
kocyte rolling, adherence, and transmigration. All statins
are potent reversible inhibitors of the key enzyme in cho-
lesterol synthesis but their pharmacological profiles differ
[86]. For instance, it was found that atorvastatin reduced
CPR and serum amyloid whilst simvastatin had little or
no effect on these variables. Levels of IL-6 and ICAM-1
were also inconsistent and little modified [87].
Moderate drinking had a lipid lowering effect and alcohol
intake, at least three to four days per week, was associated
with protection from cardiovascular events. The risk was
similar among men who consumed less than 10 g of alco-
hol per drinking day and those who consumed 30 g or
more. No single type of beverage conferred additional
benefit [88]. Alcohol intake also lowered the C reactive
protein level, independently of effects on lipids, indicat-
ing antiinflammatory activity [89]. Thus, there are several
effects of statins besides their lipid lowering activity that
could be attributed to their antiinflammatory capacity
and could be relevant to the improvement of altered local
and systemic factors.Thrombosis Journal 2003, 1 http://http//www.thrombosisjournal.com/content/1/1/4
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Obesity
It has been consistently reported that increasing degrees of
obesity are accompanied by greater rates of cardiovascular
disease [90,91]. Obesity is an independent risk factor for
major coronary events although hypercholesterolemia
and the metabolic syndrome are often associated with it
[92–94]. Obese subjects typically carry a proinflammatory
state that may predispose them to acute coronary syn-
dromes. This state is characterized by elevations of serum
CRP that reflect high cytokine levels [95]. Excess adipose
tissue secretes increased amounts of several inflammatory
cytokines. Interestingly, weight loss produces a reduction
of CRP levels [96], and serum concentrations of IL-6, IL-
18 and adiponectin levels are increased significantly [97].
This indicates that weight control could diminish the
inflammatory state. Adipose tissue present in excess also
releases increased amounts of plasminogen activator
inhibitor-1 (PAI-1), which imbalances the fibrinolytic sys-
tem towards prothrombosis [98,99].
Leptin, a circulating hormone produced by adipose tissue,
regulates body weight and food intake and metabolism. It
can influence vessel tone and an increase amount of lep-
tin, as in obesity, could contribute to arterial vessel stiff-
ness, impaired vascular function and cardiovascular
events. Leptin has angiogenic activity, increases oxidative
stress in endothelial cells which could contribute to vascu-
lar pathology, and promotes vascular cell calcification and
smooth muscle cell proliferation and migration
[100,101]. Although the release of leptin may cause local
vasodilation mediated by nitric oxide, with time it
increases oxidative stress, followed by a decrease of bioac-
tivity and / or synthesis of nitric oxide and increase of
inflammatory mediators [92].
Inflammation as an immune-mediated disease. Role of infection
Immunity
Mediators of innate and acquired immunity are involved
at various stages of atherosclerosis, as might be antici-
pated for a chronic inflammatory process [102]. In the
chronic state, atheromata contain immune cells: T lym-
phocytes, activated macrophages and mast cells, which
are also present in inflammatory infiltrates. This led to the
notion that the inflammatory response is immune-medi-
ated, and the involvement of immune mechanisms in
atherosclerosis was postulated [103]. Innate immune
reactions against bacteria and viruses have been included
in the list of pathogenic factors in atherosclerosis. Toll
Like Receptors (TLR), known to play a key role in the
innate immune response, are expressed in atherosclerotic
plaques and are associated with inflammatory activation
of endothelial cells and macrophages. The family of toll
like receptors, mainly TLR-1, 2 and 4, expressed at low lev-
els in normal endothelium, are markedly increased in
macrophages and endothelial cells of human atheroscle-
rotic lesions. Expression of TLR in cultured vascular
endothelial cells was increased by stimulation with proin-
flammatory cytokine [104]. Lipopolysaccharides released
during acute infection might link the immune response,
bacterial infection and inflammation through TLR activa-
tion in plaque cells, endothelial cells and macrophages.
This suggests a mechanism by which microbes may cause
inflammatory plaque activation. Chlamydia pneumoniae
may signal through TLR to induce the proliferation of
human vascular smooth muscle cells [105].
A recent paper by Kiechl et al [106] offers an additional
and interesting contribution to the potential importance
of TLR in the relationship between the inflammatory
response to gram-negative pathogens, innate immunity
and atherogenesis. These authors found that patients with
TLR4 polymorphism have lower levels of proinflamma-
tory cytokines, acute phase reactants, and soluble adhe-
sion molecules. Such subjects are more susceptible to
severe bacterial infection, but they have lower risk of
atherosclerosis as assessed by high-resolution duplex
ultrasonography of the carotid artery.
Some research has suggested that acute respiratory infec-
tion may be a risk factor for myocardial infarction. An
increase of acute coronary events during winter infections
and flu epidemics has been related to seasonal variations
in factor VIIa and fibrinogen, probably induced via activa-
tion of the acute phase response [107,108]. In these cir-
cumstances an immune response could support an
inflammatory process and might be associated with
increased trafficking of macrophages into the artery wall
[109]. Some studies support the assumption that influ-
enza vaccine reduces the risk of recurrent MI in patients
with documented coronary heart disease. Naghavi et al
[110] provided indications that in patients with chronic
coronary heart disease, vaccination against influenza was
negatively associated with the development of new myo-
cardial infarction during the same influenza season. The
beneficial effect of vaccination against influenza in the
elderly was indicated in the recent paper of Nichol et al.
[111].
Vaccination was associated with a reduction of 19% in the
risk of hospitalization for cardiac disease and cerebrovas-
cular disease (reduction of 16 and 23 percent during the
1998–1999 and the 1999–2000 season respectively).
Gurfinkel et al. [112] evaluated the preventive effect of
vaccination on ischemic events in myocardial infarction
patients and in subjects undergoing planned percutane-
ous coronary angioplasty. In a small number of patients
suffering from infarction, but not in those recovering from
angioplasty, influenza vaccination reduced the risk of
death and ischemic events.Thrombosis Journal 2003, 1 http://http//www.thrombosisjournal.com/content/1/1/4
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The antiphospholipid syndrome considered an autoim-
mune disease triggering endothelial cellular disturbance,
produces arterial and venous thrombosis [113,114]. The
high affinity of antiphospholipid antibody-β2GPI com-
plex for phospholipid membranes seems to be a critical
factor in this disease [115]. Activation of endothelial cells
and enhanced thrombosis by antiphospholipid seem to
be mediated by ICAM-1, P-selectin, or VCAM-1 [116].
The humoral immune response could be a high risk factor
for coronary heart disease, inducing inflammation that
links immunity with coronary disease.
Infection
Infection and the immune local reaction cause endothe-
lial dysfuction, cell injury, and a proinflammatory envi-
ronment. Whether infection is the main factor involved in
inflammation remains unproved [117–125]. Endotoxins
secreted by bacteria are potent activators of different
inflammatory reactions, stimulating circulating mono-
cytes and causing production of several cytokines. They
may also disturb hemostasis [126].
Interleukin-18 gene expression is stimulated by proin-
flammatory cytokines and also by lipopolysaccharides. If
infection is also a trigger of interleukin-18 this could
explain the relationships between inflammation and
infection and the controversial association between previ-
ous infection and cardiovascular events. It could also
explain the erratic effects of antibiotics on the prevention
of coronary artery disease.
Expression of toll like receptors in atheroma is a suggested
mechanism for inflammatory plaque activation by
microbes [105].
Figure 1
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Many seroepidemiology studies suggest a relationship
between infection and the pathophysiology of ischemic
heart disease and the severity of atherosclerosis [126,127].
Chlamydia pneumoniae, cytomegalovirus and Helicobacter
pylori have been associated with atherosclerotic lesions.
Moreover, viral and bacterial proteins can induce anti-
phospholipid antibody production in humans which
could be an additional factor attacking endothelium
[128]. Of these candidate organisms, Chlamydia pneumo-
niae appears most likely to be involved in coronary dis-
ease through different mechanisms. Chlamydia
pneumoniae can be replicated and maintained in human
macrophages and in endothelial cells. Thus it can partici-
pate in the acute coronary process through a direct effect
on atheroma, initiating the inflammatory process, or it
can remain latent in the atheroma as a bystander, subse-
quently being activated during inflammation and acutely
exacerbating the response. Alternatively, atheroma might
be colonized by Chlamydia pneumoniae during plaque
inflammation, contributing to plaque disruption.
The controversial role of Chlamydia pneumoniae in coro-
nary events was also indicated by the effect of antibiotic
treatment.  Chlamydia pneumoniae is sensitive to mac-
rolides (azithromycin, roxithromycin and clarithromy-
cin) [129], but besides their anti-infectious activity, an
alternative mechanism for macrolides was suggested
[130–132]: they could suppress macrophage activity,
which means they could have antiinflammatory effects,
different for each drug. Controversial results could be
related to these different antiinflammatory effects.
Homocysteine
Elevated circulating homocysteine (tHcy) level is a risk
factor for occlusive disease in the coronary, cerebral, and
peripheral vessels and predictive of survival in patients
with stable coronary artery disease. Nevertheless a causal
relation still remains to be proven [133–136].
The Homocysteine Studies Collaboration concludes that
evidence of a link between higher homocysteine levels
and the risk of coronary disease is weaker than previously
reported [137]. It had been suggested that serum homo-
cysteine level on hospital admission was an independent
predictor of long-term survival in patients with acute cor-
onary syndromes, but a meta-analysis of the observational
studies suggests only a modest independent prediction of
ischemic heart disease and stroke risk in healthy popula-
tions. Nurk et al. [138] provide evidence that plasma
homocysteine level is a strong predictor of cardiovascular
disease only in elderly patients, and especially among
those with preexisting cardiovascular disease. Thus homo-
cysteine interacts with conventional risk factors to pro-
voke the acute event. Klerk et al. [139] indicate that
individuals with the MTHFR 677 TT genotype have a sig-
nificantly higher risk of coronary heart disease, particu-
larly in the setting of low folate status, and support the
hypothesis that impaired folate metabolism, resulting in
high homocysteine levels, is causally related to a 16%
increased risk of coronary heart disease. Nevertheless, the
excess risk was evident only in European studies, not in
North American investigations [139].
The link between homocysteine and coronary disease may
be mediated by activation of coagulation and alteration of
the vasomotor regulatory and anticoagulant properties of
endothelial cells [140–142]. Impaired homocysteine
metabolism may result in oxidative stress [143], which
might play a central role in hyperhomocysteinemia-medi-
ated vascular disorders [144,145]. Homocysteine
increases TNF-expression, which enhances oxidative stress
and induces a proinflammatory vascular state that may
contribute to the development of coronary atherosclerosis
[146].
It has also been suggested that enhanced peroxidation of
arachidonic acid to form bioactive F2-isoprostanes could
represent the mechanism linking hyperhomocysteinemia
to platelet activation in cystathionine β-synthase deficient
patients [147].
A recent report showed that folic acid, vitamin B12, and
pyridoxine significantly reduce homocysteine levels, the
rate of restenosis and the need for revascularization after
coronary angioplasty [148,149]. But in the paper by
Doshi et al., folic acid 5 mg/d for 6 weeks improved
endothelial function, as assessed by flow-mediated dilata-
tion in cardiovascular artery disease, by a mechanism
independent of homocysteine [150].
Hypertension
The renin-angiotensin system contributes to the patho-
genesis of atherosclerosis. Its effect on blood pressure par-
tially explains this; also, angiotensin II may elicit
inflammatory signals in vascular smooth muscle cells. The
transcription factor NF-κB participates in most signaling
pathways involved in inflammation [151]. Angiotensin II
is a regulator of the NF-κB family and may be responsible
for activating the expression of cytokine gene networks in
vascular smooth muscle cells. It can also promote long-
term changes in vascular smooth muscle cell function by
its ability to induce cellular hypertrophy, extracellular
matrix production, and early gene expression [152]. Angi-
otensin II also activates inflammatory pathways in human
monocytes.
L-Arginine, a nitric oxide precursor that augments
endothelium-dependent vasodilatation, acutely improves
endothelium-dependent, flow-mediated dilatation of the
brachial artery in patients with essential hypertensionThrombosis Journal 2003, 1 http://http//www.thrombosisjournal.com/content/1/1/4
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[153]. As mentioned during the discussion of other risk
factors, inflammation may link hypertension and athero-
sclerosis, and the clinical benefits of treatment with angi-
otensin-converting enzyme inhibitor may to some extent
derive from interrupting inflammation [31].
Smoking
Cigarette smoking is a major risk factor for developing
coronary artery disease, producing a marked decline in
endothelium-dependent vasomotor response [154–156].
It causes endothelial dysfunction, possibly through
increased oxidative stress, and this is also true for passive
smoking or environmental tobacco smoke. A 30-minute
passive smoking exposure was found to affect coronary
flow velocity reserve in nonsmokers [157]. Light and
heavy smoking have similar detrimental effects on
endothelium-dependent vasodilation and the nitric oxide
biosynthetic pathway [158]. Significant increases of
sICAM-1 and sVCAM-1 were demonstrated in smokers,
and nitric oxide metabolites were reduced significantly
[159]. Smoking-induced endothelial dysfunction of
resistance vessels is rapidly reversed with oral allopurinol.
These data suggest that xanthine oxidase contributes
importantly to the endothelial dysfunction caused by cig-
arette smoking [160]. Folic acid significantly improves
endothelial function in otherwise healthy cigarette smok-
ers. This provides a potential therapeutic tool for attenuat-
ing the atheromatous process in this group [161].
Conclusions
The new findings add evidence for a close relationship
between risk factors, inflammation and atherosclerosis.
Inflammation is the common response of endothelial
cells to different factors that attack arterial intima. Taking
into account this chain of local arterial endothelial cell
reactions, the behavior of inflammation markers, and the
effects of specific drugs that possess additional anti-
inflammatory effects, the concept of athero-inflammation
emerges as the meeting point of different morbidities,
usually named as risk factors, which include dyslipemia,
diabetes, hypertension, obesity, immunity, infection,
hyperhomocyteinemia, smoking (Figure).
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